ORIC PHARMACEUTICALS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ORIC PHARMACEUTICALS, INC. (ORIC) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$41.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$41.49M.
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$35.77M.
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$32.59M.
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$36.35M.
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$129.47M.
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$127.85M.
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$100.70M.
- ORIC PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$89.12M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$41.49M 10-Q · filed 2026-08-03 | -$77.26M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2026-03-31 | -$35.77M 10-Q · filed 2026-08-03 | ||||
| 2025-12-31 | -$129.47M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$32.59M 10-Q · filed 2025-11-13 | -$68.94M derived: sum of 2 quarters · filed 2026-08-03 | -$98.96M derived: sum of 3 quarters · filed 2026-08-03 | ||
| 2025-06-30 | -$36.35M 10-Q · filed 2026-08-03 | -$66.38M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2025-03-31 | -$30.02M 10-Q · filed 2026-08-03 | ||||
| 2024-12-31 | -$127.85M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | -$34.57M 10-Q · filed 2025-11-13 | -$66.53M derived: sum of 2 quarters · filed 2025-11-13 | -$91.54M derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$31.96M 10-Q · filed 2025-11-13 | -$56.97M derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | -$25.01M 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | -$100.70M 10-K · filed 2025-02-18 | ||||
| 2023-09-30 | -$25.48M 10-Q · filed 2024-11-12 | -$48.42M derived: sum of 2 quarters · filed 2024-11-12 | -$72.37M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$22.94M 10-Q · filed 2024-11-12 | -$46.89M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | -$23.95M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | -$89.12M 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | -$24.83M 10-Q · filed 2023-11-06 | -$45.12M derived: sum of 2 quarters · filed 2023-11-06 | -$68.28M derived: sum of 3 quarters · filed 2023-11-06 | ||
| 2022-06-30 | -$20.29M 10-Q · filed 2023-11-06 | -$43.45M derived: sum of 2 quarters · filed 2023-11-06 | |||
| 2022-03-31 | -$23.16M 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | -$78.72M 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | -$18.43M 10-Q · filed 2022-11-07 | -$39.44M derived: sum of 2 quarters · filed 2022-11-07 | -$55.94M derived: sum of 3 quarters · filed 2022-11-07 | ||
| 2021-06-30 | -$21.01M 10-Q · filed 2022-11-07 | -$37.52M derived: sum of 2 quarters · filed 2022-11-07 | |||
| 2021-03-31 | -$16.51M 10-Q · filed 2022-11-07 | -$16.46M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | -$73.70M 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | -$25.55M 10-Q · filed 2021-11-08 | -$36.57M derived: sum of 2 quarters · filed 2021-11-08 | -$45.44M derived: sum of 3 quarters · filed 2021-11-08 | ||
| 2020-06-30 | -$11.02M 10-Q · filed 2021-11-08 | -$19.90M derived: sum of 2 quarters · filed 2021-11-08 | |||
| 2020-03-31 | -$8.87M 10-Q · filed 2021-11-08 | ||||
| 2019-12-31 | -$26.88M 10-K · filed 2022-03-21 | ||||
| 2019-09-30 | -$6.55M 10-Q · filed 2020-11-05 | -$12.51M derived: sum of 2 quarters · filed 2020-11-05 | -$18.53M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | -$5.96M 10-Q · filed 2020-11-05 | -$11.98M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | -$6.01M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | -$21.36M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |